Dr. Haijin Meng has over 20 years of experience in the pharmaceutical industry, with broad R&D management expertise spanning from pre-IND/IND application, successful NDA/BLA registration, to post-approval product lifecycle management. She has worked in hospitals, universities, academic institutes, MNC pharmaceutical companies, various stages of startups and joint-venture firms.

Before joining Chengdu New Radiomedicine Technology Co., Ltd., Dr. Meng held several senior roles including Medical Head of External Strategic Collaboration at Pfizer China; Head of Early Clinical Development at Bristol-Myers Squibb China; Vice President and Chief Medical Officer at Gloria Bioscience; Chief Scientific Officer at Shanghai Pharma-BIOCAD China; Chief Medical Officer at Nuance Pharma; and Chief Medical Officer at SUNGEN Pharmaceuticals. Dr. Meng has previously engaged in innovative drug development across multiple therapeutic areas, including cardio- and cerebro-vascular diseases, endocrinology, gastroenterology, respiratory diseases, immuno-oncology, autoimmune disorders, CNS pain, and pediatrics. She is well-versed in ICH-GCP guidelines and familiar with regulatory principles and collaboration models for the FDA, NMPA, and EMA, and has organized and executed multiple multinational MRCTs.